|
Association of metagene based on gene expression with response to atezolizumab (atezo) for metastatic urothelial carcinoma (mUC). |
|
|
|
|
Stock and Other Ownership Interests - Halo Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
Research Funding - IBM (Inst); Pharmacyclics (Inst) |
Patents, Royalties, Other Intellectual Property - Patents related to bioinformatic tools (Inst) |
|
|
|
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi |
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice |
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group |